Muvalaplin, an Oral Small Molecule Inhibitor of Lipoprotein(a) Formation: A Randomized Clinical Trial.
Nicholls SJ, Nissen SE, Fleming C, Urva S, Suico J, Berg PH, Linnebjerg H, Ruotolo G, Turner PK, Michael LF.
JAMA. 2023 Sep 19;330(11):1042-1053. doi: 10.1001/jama.2023.16503.
Target inhibition of galectin-3 by inhaled TD139 in patients with idiopathic pulmonary fibrosis.
Hirani N, MacKinnon AC, Nicol L, Ford P, Schambye H, Pedersen A, Nilsson UJ, Leffler H, Sethi T, Tantawi S, Gravelle L, Slack RJ, Mills R, Karmakar U, Humphries D, Zetterberg F, Keeling L, Paul L, Molyneaux PL, Li F, Funston W, Forrest IA, Simpson AJ, Gibbons MA, Maher TM.
Eur Respir J. 2021 May 27;57(5):2002559. doi: 10.1183/13993003.02559-2020. Print 2021 May.
Single-bolus tenecteplase compared with front-loaded alteplase in acute myocardial infarction: the ASSENT-2 double-blind randomised trial.
Assessment of the Safety and Efficacy of a New Thrombolytic (ASSENT-2) Investigators; Van De Werf F, Adgey J, Ardissino D, Armstrong PW, Aylward P, Barbash G, Betriu A, Binbrek AS, Califf R, Diaz R, Fanebust R, Fox K, Granger C, Heikkilä J, Husted S, Jansky P, Langer A, Lupi E, Maseri A, Meyer J, Mlczoch J, Mocceti D, Myburgh D, Oto A, Paolasso E, Pehrsson K, Seabra-Gomes R, Soares-Piegas L, Sùgrue D, Tendera M, Topol E, Toutouzas P, Vahanian A, Verheugt F, Wallentin L, White H.
Lancet. 1999 Aug 28;354(9180):716-22. doi: 10.1016/s0140-6736(99)07403-6.
Inflammatory proteins associated with Alzheimer's disease reduced by a GLP1 receptor agonist: a post hoc analysis of the EXSCEL randomized placebo controlled trial.
Koychev I, Reid G, Nguyen M, Mentz RJ, Joyce D, Shah SH, Holman RR.
Alzheimers Res Ther. 2024 Oct 2;16(1):212. doi: 10.1186/s13195-024-01573-x.
Cutaneous and plasma fibrinolytic activity in systemic sclerosis. Evidence of normal plasminogen activation.
Matucci-Cerinic M, Lotti T, Lombardi A, Pignone A, Iannone F, Beneforti E, Cinotti S, Morfini M, Caignoni M.
Int J Dermatol. 1990 Nov;29(9):644-8. doi: 10.1111/j.1365-4362.1990.tb02587.x.
Clinical Pharmacokinetics and Pharmacodynamics of Desmoteplase.
Piechowski-Jozwiak B, Abidi E, El Nekidy WS, Bogousslavsky J.
Eur J Drug Metab Pharmacokinet. 2022 Mar;47(2):165-176. doi: 10.1007/s13318-021-00743-8. Epub 2021 Dec 11.
A rapid screening test for reduced fibrinolytic activity of plasma: streptokinase activated lysis time.
Gidron E, Margalit R, Shalitin Y.
J Clin Pathol. 1978 Jan;31(1):54-7. doi: 10.1136/jcp.31.1.54.
Mannose-binding lectin-associated serine protease-1 cleaves plasminogen and plasma fibronectin: prefers plasminogen over known fibrinogen substrate.
Choudhary K, Patel PK, Are VN, Makde RD, Hajela K.
Blood Coagul Fibrinolysis. 2021 Oct 1;32(7):504-512. doi: 10.1097/MBC.0000000000001074.
Fibrinolytic Changes in Women with Preeclampsia.
Godtfredsen AC, Sidelmann JJ, Dolleris BB, Jørgensen JS, Johansen EKJ, Pedersen MFB, Palarasah Y, Gram JB.
Clin Appl Thromb Hemost. 2022 Jan-Dec;28:10760296221126172. doi: 10.1177/10760296221126172.
Plasma is the physiologic buffer of tissue plasminogen activator-mediated fibrinolysis: rationale for plasma-first resuscitation after life-threatening hemorrhage.
Moore HB, Moore EE, Gonzalez E, Wiener G, Chapman MP, Dzieciatkowska M, Sauaia A, Banerjee A, Hansen KC, Silliman C.
J Am Coll Surg. 2015 May;220(5):872-9. doi: 10.1016/j.jamcollsurg.2015.01.026. Epub 2015 Mar 31.
